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Ischemic mitral regurgitation redux—To repair or to
replace?
D. Craig Miller, MD
“Most often the entire valve appears normal; . . . There is little to fix, yet the valve
leaks. . . . the valve is structurally normal; it need not be replaced, but currently we
do not know how to fix it . . . .”
—L. Henry Edmunds, Jr, 19971
The pair of articles in this issue of the Journal by Gillinov,2 Grossi,3and their colleagues revisits an old and unanswered question: Is itbetter to repair or replace the leaking mitral valve in patients withcoronary artery disease that has caused ischemic mitral regurgitation(IMR)? These two articles bring contemporary clarity to this di-lemma and represent a major step forward, but they do not answer all
our questions.
This controversy was reignited in 1995 by Lawrence Cohn and his colleagues4
from the Brigham, who reported that the outcome of patients with IMR undergoing
mitral repair or mitral valve replacement (MVR) plus coronary artery bypass
grafting (CABG) was not so much dependent on the choice of operative procedure
per se, but more on the underlying pathophysiology of the IMR and the patient’s
clinical presentation. This enlightened certain surgeons who had already convinced
themselves that repair was better, but also reminded us that the prognosis for these
sick patients was markedly suboptimal. Patients with IMR have morphologically
normal mitral leaflets and subvalvular apparatus, but the valve can leak badly.
Previously, surgeons had not talked a lot about IMR, perhaps because none of our
surgical results were particularly good. Subsequently, we learned conclusively in the
multicenter SAVE (Survival and Ventricular Enlargement) trial that even a mild
degree of mitral regurgitation (MR) portended a substantial excessive risk of
cardiovascular mortality within 5 years after acute myocardial infarction,5 even in
patients who did not have any overt signs of congestive heart failure at the time of
study entry. These data reinforced the results of prior observational studies of
patients with IMR, both those treated medically after a myocardial infarction and
those undergoing CABG or percutaneous transluminal coronary angioplasty.
Earlier retrospective surgical studies included patients with many different types
of mitral valve disease, including those with prolapse found to have incidental
coronary artery disease, which only confounded the issue. One beauty of the two
articles published in this issue of the Journal is that only patients with IMR caused
by coronary artery disease were investigated; that is, these are “clean” studies.
Second, these papers used strict pathophysiologic criteria to classify the patients
with respect to the mechanism of IMR. Even though different descriptive terms were
used, an important message is that we distinguish between “functional IMR,”
infarcted but not ruptured papillary muscle, and ruptured papillary muscle. The vast
majority is represented by patients with functional IMR, which can be due to one of
the following reasons: (1) simple annular dilatation (secondary to left ventricular
[LV] enlargement), which causes incomplete mitral leaflet coaptation associated
with Carpentier type I (normal) leaflet motion; (2) local LV remodeling with
papillary muscle displacement producing apical tethering or tenting of the leaflets
(with Carpentier type III-b restricted systolic leaflet motion); or (3) both mecha-
nisms. Importantly, exhaustive analyses from the Mayo Clinic echocardiography
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laboratory6,7 have provided a great amount of insight into
the mechanisms of IMR and its clinical impact. Thanks to
these investigators, we can now reliably measure leaflet
tenting area and tenting height quantitatively from transtho-
racic echocardiograms in patients with LV dysfunction and
IMR or functional MR, as well as estimate the effective
regurgitant orifice.6 Larger effective regurgitant orifice, or
more leak, was directly and independently predicted by
excess leaflet tenting and loss of systolic annular contrac-
tion, but it was not related to the degree of LV dysfunction.
Adverse prognostic consequences were also clearly docu-
mented, moreover, as medium-term survival for patients
with IMR and LV dysfunction was strongly and indepen-
dently related to calculated effective regurgitant orifice,
even after statistical adjustment for all other variables.7
Recently, Otsuji and associates,8 working in Vlahakes’ and
Levine’s laboratory at the Massachusetts General Hospital,
experimenting with short-term canine and long-term sheep
models and 3-dimensional echocardiographic imaging, also
contributed new information concerning the mechanisms of
IMR resulting from LV local remodeling.
Now that we better understand what we are talking about
(and can actually measure it!), surgeons should be more
aggressive and not ignore substantial degrees of IMR at the
time of CABG. This policy should also apply to patients
undergoing percutaneous coronary revascularization with
percutaneous transluminal coronary angioplasty and stent-
ing to optimize their prognosis, but such is unlikely since we
do not live in a utopia and the interventional cardiologists
have not figured out quite yet how to repair leaking mitral
valves in the cardiac catheterization laboratory.
But, does one do a ring annuloplasty or a more reliable
chordal-preserving MVR? As the authors of the two accom-
panying articles declare,2,3 the answer is not a simple one.
Historically, we have been handicapped by comparing very
different cohorts of patients in attempting to assess whether
repair offers a better outcome than does MVR. The patients
receiving these two procedures were very dissimilar and not
directly comparable, truly an apples versus oranges situa-
tion. Fallacious conclusions resulted from such compari-
sons. In the absence of randomized trials, which are prob-
ably unrealistic, this handicap persists as demonstrated in
both accompanying papers2,3; but, new statistical tools are
now available that can help neutralize the inherent patient
selection bias that plagues such retrospective studies. In the
Gillinov analysis of 482 patients,2 Blackstone used propen-
sity score analysis and other sophisticated statistical meth-
ods to generate quintiles of patients undergoing either repair
or MVR that were relatively well matched to answer the
question whether one procedure is better than the other, and,
if so, in which particular patient. This approach identified
subsets of patients (unbalanced in numbers) that were rea-
sonably well balanced in terms of risk factors. Bootstrap
resampling (so-called “bagging”) was also used to validate
the results of the model and confirm that the results were
generalizable. This important paper (together with the ap-
pendixes) deserves to be read carefully and repeatedly; it is
remarkable for its clarity of prose (even though it is written
in a tongue that I affectionately call “Gene-speak”). A
massive amount of effort was invested, including Gillinov
reviewing all available original echocardiographic tapes to
reclassify the patient population. About 70% of patients—
but not the sickest patients—were believed to benefit from
repair. The amount of relative benefit of repair in terms of
survival was less or actually erased if a thoracic artery was
not used for CABG, a lateral LV wall motion abnormality
was present, or the IMR jet was “complex.” The sickest
patients did equally poorly with either procedure, and in
certain cases MVR was in fact associated with better pre-
dicted survival. Overall 5-year survival was still disappoint-
ing, regardless of whether the valve was repaired or re-
placed.
Propensity score analysis was also explored by Grossi
and associates,3 who evaluated 223 patients with IMR; but,
the New York University statisticians concluded that the
marked imbalance in numbers of patients undergoing one
procedure or another within the quintiles was such that the
propensity score models did not provide an adequate fit to
the data. Therefore, propensity score adjustments were not
used. Instead, the New York University group did multiple
convoluted layers of multivariable analyses to adjust for the
confounding effects of functional disability (New York
Heart Association class), presence of angina, and particular
operation performed, followed by separate Cox modeling
within each of the two surgical groups. The nuances of this
arcane statistical debate are best left to the professional
biostatisticians, whom I invite to air their differences in
public so as to educate the rest of us. Perhaps propensity
score analysis worked in the Cleveland Clinic series be-
cause it comprised more than twice the number of patients
as did the New York University series. Fortunately, several
invited papers concerning these statistical topics will be
forthcoming soon in the Journal. Suffice it to say, the
patients who underwent mitral repair at New York Univer-
sity were not as sick as those who required MVR (as was
also the case in the Gillinov report2); medium-term survival
was suboptimal but roughly equivalent between the two
types of procedures. Certain subsets of patients were iden-
tified who appeared to do better if they could undergo
repair. This lack of pronounced difference in survival be-
tween the repair and the MVR groups is similar to the
conclusions just reported by Calafiore and colleagues9 in
patients with functional MR and incomplete mitral leaflet
coaptation due to dilated idiopathic cardiomyopathy (n 
12) or IMR due to ischemic cardiomyopathy (n  7), but
certain differences beg amplification. In the Italian experi-
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ence,9 recurrence of MR was frequent after repair if what
Calafiore called mitral valve coaptation depth (which is
equivalent to the Mayo term “coaptation height”6 and in-
dicative of apical leaflet tenting) was 11 mm or greater; this
stands to reason as no matter how small one makes the
mitral anulus, this maneuver cannot recreate competent
leaflet coaptation if one or both leaflets are extensively
apically tethered because of papillary muscle displacement.
If one wants to save the valve in these cases, more radical
repair procedures are required, such as external LV plication
or buttressing,8 realignment of papillary muscle geometry
inside the ventricle, leaflet patch extension as described by
Dobre, Koul, and Rojer,10 or perhaps an Alfieri stitch.
Second, the mitral reparative procedures performed in Cala-
fiore’s series included pericardial strip annuloplasty or a
modified De Vega-type or Paneth-type continuous suture
annuloplasty, which have been abandoned by most sur-
geons. In the Cleveland Clinic2 and the New York Univer-
sity3 articles, both of these techniques were much less
effective than implantation of a synthetic mitral annulo-
plasty band or ring.
Despite my enthusiasm to see these two articles finally
published and my appreciation of their clinical value, one
must still be a little circumspect.
1. Neither study2,3 included a control group of patients
that had comparable degrees of IMR but underwent
CABG only; hence, what Donald Glower calls the
“straw man hypothesis” exists, again.
2. Two other important end-points were not evaluated in
either study: (a) the impact of mitral repair versus
MVR on LV systolic function over time and (b) the
adequacy of the repair as assessed by serial echocar-
diographic surveillance. Although the incidence of
reoperation after repair was low, this could be mis-
leading for two reasons: (I) many patients could have
had recurrent IMR but been so sick they were not
considered suitable candidates for reoperation and (II)
the death rates were so high that relatively few pa-
tients remained at risk for structural valve deteriora-
tion of the repair beyond 2 to 3 years. These two
essential end-points should be the focus of future
investigations.
3. Finally, despite whatever procedure was performed,
the 5-year survival was still not much better than
50%. This indicates that successful revascularization
and correction of the IMR does relatively little in
terms of ameliorating the ravages of previous LV
infarction and ischemia.
The Bottom Line
Patients with IMR represent a heterogeneous group that has
a soberingly dismal medium-term prognosis because of
underlying LV systolic dysfunction. As Steven Bolling is
wont to say: “IMR is a ventricular disease, not a valvular
disease.” We now recognize that ignoring an important
degree of IMR at the time of CABG is not prudent because
it will only limit the potential functional benefit to be
attained from operation and compound the patient’s poor
life expectancy. One exception to this policy would be the
uncommon situation where an inferior LV wall motion
abnormality causing IMR is known preoperatively to be due
to reversible ischemia involving viable myocardium, such
that revascularization alone has a high likelihood of correct-
ing the IMR.
Valve repair with an undersized annuloplasty ring works
satisfactorily in most cases of functional IMR, but the
surgeon needs to pay keen attention in interpreting the
genesis and direction of the MR leak. If simple annular
dilatation resulting in incomplete mitral leaflet coaptation
and associated with Carpentier type I leaflet motion is the
main culprit and the leak is centrally directed straight back
into the atrium or slightly posteriorly directed (due to “pseu-
do-prolapse” of the anterior leaflet, which reflects restriction
of the posterior leaflet), then it is likely that simple ring
annuloplasty will work well and will be fairly durable;
conversely, if the pattern of the IMR leak is complex, or
substantial apical tenting of the leaflets is identified (Car-
pentier type III-b restricted systolic leaflet motion), or a
lateral wall infarct is present, then simple ring annuloplasty
may not be the most prudent course of action. The most
important surgical goal in repairing the valve is to reduce
and fix the mitral annular dimension in the anterior-poste-
rior (or “septal-lateral” in anatomic terms) axis, not the
commissure-commissure axis. Although both partial or
complete and flexible or rigid rings perform satisfactorily,2,3
in theory this goal may best be accomplished in patients
with IMR by using stiffer rings, for example, Carpentier-
Edwards Classic (not Physio) (Edwards Lifesciences, Ir-
vine, Calif), Carbomedics AnnuloFlo (Sulzer Carbomedics,
Austin, Tex), or the newly approved Medtronic CG Future
Band (a partial, semirigid ring, Medtronic Heart Valve
Division, Minneapolis, Minn), developed by Colvin, Gallo-
way, and Grossi. This is despite the fact that the first two
types of ring completely abolish annular dynamic motion
and in contrast to patients with mitral prolapse, in whom a
flexible, partial (posterior only) band is preferred by me and
many others.
Surgeons today frequently are taking a more aggressive
approach and adding a mitral ring during coronary revas-
cularization if substantial IMR is present. Does this mean
that all patients undergoing CABG who have more than
mild MR should receive concomitant mitral annuloplasty?
Probably not. Such enhances the risk of air embolism and
prolongs cardiopulmonary bypass time, which is likely to
increase the already high operative mortality risk because
these patients invariably have poor LV systolic func-
tion.2,3,9,11 This judgment decision needs to be based on the
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severity and the mechanism of the IMR as assessed on the
preoperative echocardiogram under stress or ambulatory
hemodynamic conditions; assessment intraoperatively by
transesophageal echocardiography is unreliable and often
misleading because of the LV pressure and volume unload-
ing effects of general anesthesia. Given our current excel-
lent methods of myocardial protection, making an error of
commission rather than one of omission with respect to ring
annuloplasty is perhaps the most sensible course of action
when one is uncertain; however, again, the nature and
mechanism of the IMR leak needs to be fully appreciated.
Without a doubt, a role still remains for MVR, especially
if all anterior and posterior leaflet chordae are preserved.
This reasonable alternative may be preferable for surgeons
who do not do many dozens of mitral repair procedures each
year. Other circumstances in which a quick and dependable
MVR may be the better side of valor when facing functional
IMR include the very sickest patients, those with a complex
MR leak or a lateral LV wall motion abnormality, and
patients with considerable apical leaflet tenting. Addition-
ally, individuals with an infarcted or ruptured papillary
muscle and very ill patients presenting on an emergency
basis after an acute myocardial infarction probably are best
served by chordal-sparing MVR. Given the markedly lim-
ited life expectancy of patients with IMR, it does not make
any sense to use a mechanical prosthesis for MVR, irre-
spective of the patient’s age; a tissue valve is indicated
because very few of these patients will actually live long
enough to sustain structural deterioration of their biopros-
thesis. Further, saving all the subvalvular apparatus is less
technically demanding and fraught with fewer potential
postoperative valve-related complications if a bioprosthesis
is used.
I respect the cardiac surgeons at these two institutions,
and I salute them and their statistical coworkers for their
honesty and candor. Thanks to a huge amount of hard work
on their part, our knowledge base concerning the surgical
treatment of patients with IMR is more complete after
publication of these two articles.
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